UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical cancer research, 2021-05, Vol.27 (9), p.2435-2441

2021

Volltextzugriff (PDF)

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

Clinical cancer research, 2020-02, Vol.26 (4), p.804-811

2020

Volltextzugriff (PDF)

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European urology, 2023-09, Vol.84 (3), p.341-347

2023

Volltextzugriff (PDF)

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma research, 2021-02, Vol.31 (1), p.27

2021

Volltextzugriff (PDF)

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.44-49

2018

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2011-02, Vol.17 (4), p.849-860

2011

Volltextzugriff (PDF)

Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

Cancer research communications, 2024-05, Vol.4 (5), p.1369-1379

2024

Volltextzugriff (PDF)

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Cancer research communications, 2024-04, Vol.4 (4), p.1100-1110

2024

Volltextzugriff (PDF)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Neuro-oncology advances, 2022-01, Vol.4 (1), p.vdac012

2022

Volltextzugriff (PDF)

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2011-05, Vol.17 (10), p.3431-3442

2011

Volltextzugriff (PDF)

Participation in phase I oncology trials by minorities: Survival and compliance data

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18628-e18628

2023

Volltextzugriff (PDF)

Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-04, Vol.5 (4), p.533-539

2010

Volltextzugriff (PDF)

A community hospital experience on the outcome of patients with different genetic variant epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19099-e19099

2014

Volltextzugriff (PDF)

A community hospital experience in the use of peri-operative dose-dense MVAC in patients with muscle-invasive bladder cancer (MIBC) treated with either robotic cystectomy (RC) or open cystectomy (OC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e15509-e15509

2014

Volltextzugriff (PDF)

Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4592-4592

2023

Volltextzugriff (PDF)

Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4588-4588

2023

Volltextzugriff (PDF)

Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2624-2624

2023

Volltextzugriff (PDF)

Characterization and impact of Wnt5A signaling on outcomes of urothelial carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.560-560

2023

Volltextzugriff (PDF)

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2051-2051

2021

Volltextzugriff (PDF)

Perioperative DD-MVAC as a safe and efficacious treatment for MIBC: Results of a retrospective community center study with clinical correlates of toxicity and response

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15540-e15540

2015

Volltextzugriff (PDF)

A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3005-3005

2022

Volltextzugriff (PDF)

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.536-536

2022

Volltextzugriff (PDF)

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3507-3507

2020

Volltextzugriff (PDF)

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9506-9506

2019

Volltextzugriff (PDF)

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9560-9560

2020

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAlzheimer's & Dementia

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(31)
Humans
(19)
Technology
(12)
Engineering Sciences
(9)
Micro And Nanotechnologies
(9)
Microelectronics
(9)
Oncology
(9)
Engineering
(8)
Engineering, Electrical & Electronic
(8)
Female
(8)
Male
(8)
Adult
(7)
Computer Science
(7)
Aged
(6)
Neurosciences & Neurology
(6)
Physical Sciences
(6)
Biological And Medical Sciences
(5)
Brazil
(5)
Circuit Faults
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors

Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

Participation in phase I oncology trials by minorities: Survival and compliance data

Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer

A community hospital experience on the outcome of patients with different genetic variant epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

A community hospital experience in the use of peri-operative dose-dense MVAC in patients with muscle-invasive bladder cancer (MIBC) treated with either robotic cystectomy (RC) or open cystectomy (OC)

Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis

Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder

Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies

Characterization and impact of Wnt5A signaling on outcomes of urothelial carcinoma

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors

Perioperative DD-MVAC as a safe and efficacious treatment for MIBC: Results of a retrospective community center study with clinical correlates of toxicity and response

A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo)

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2

Aktive Filter

Suchergebnisse filtern